Protara Therapeutics(TARA) - 2025 Q4 - Annual Results

Clinical Trials and Product Development - TARA-002 demonstrated a 68% complete response rate at six months in BCG-Unresponsive patients in the ADVANCED-2 trial[1] - The company expects to complete enrollment of the BCG-Unresponsive cohort in the ADVANCED-2 trial in the second half of 2026[1] - The company expects to report interim results from the THRIVE-3 registrational trial of IV Choline Chloride in the second half of 2026[1][4] - TARA-002 received Breakthrough Therapy and Fast Track designations for lymphatic malformations, with a regulatory update expected in the first half of 2026[1][7] - The BCG-Naïve cohort of patients in the ADVANCED-2 trial demonstrated a complete response rate of 72.4% at any time[3] - The majority of treatment-related adverse events for TARA-002 were Grade 1 and transient, with no Grade 3 or greater events reported[3] Financial Performance - Protara incurred a net loss of $17.3 million, or $0.37 per share, for Q4 2025, compared to a net loss of $12.8 million, or $0.48 per share, for the same period in 2024[8] - The net loss for the year ended December 31, 2025, was $57,439,000, compared to a net loss of $44,596,000 in 2024, indicating an increase in losses of approximately 28.8%[20] - Protara reported a net income (loss) per share attributable to common stockholders of $(1.34) for 2025, compared to $(2.17) for 2024, showing an improvement in loss per share[20] Expenses and Assets - Research and development expenses for Q4 2025 increased to $13.1 million from $9.5 million in Q4 2024, and for the full year increased to $42.6 million from $31.7 million in 2024[8] - General and administrative expenses for Q4 2025 rose to $6.0 million from $4.8 million in Q4 2024, and for the full year increased to $21.9 million from $17.5 million in 2024[8] - Total operating expenses for the year ended December 31, 2025, were $64,549,000, up from $49,154,000 in 2024, marking an increase of approximately 31.3%[20] - Research and development expenses rose to $42,633,000 in 2025 from $31,704,000 in 2024, reflecting a growth of about 34.5%[20] Cash and Assets Management - Protara completed an oversubscribed public offering raising $86 million, with cash and investments totaling approximately $198 million as of December 31, 2025, expected to support operations into 2028[1][8] - Protara's total current assets decreased from $172,155,000 in 2024 to $159,504,000 in 2025, a decline of approximately 7.7%[18] - The company's cash and cash equivalents significantly dropped from $162,798,000 in 2024 to $49,657,000 in 2025, representing a decrease of about 69.5%[18] - The company's stockholders' equity increased from $167,134,000 in 2024 to $196,412,000 in 2025, an increase of approximately 17.5%[18] - Protara's total liabilities decreased slightly from $14,320,000 in 2024 to $13,056,000 in 2025, a reduction of about 8.8%[18] Shareholder Information - The weighted-average shares outstanding for basic and diluted earnings per share increased from 20,592,847 in 2024 to 42,836,129 in 2025, more than doubling the share count[20] - The company anticipates ongoing development plans for its product candidates and expects to engage with the U.S. Food and Drug Administration regarding future clinical trials[15]